{"id":20849,"date":"2026-03-29T16:50:30","date_gmt":"2026-03-29T15:50:30","guid":{"rendered":"https:\/\/drugprevent.org.uk\/ppp\/?p=20849"},"modified":"2026-03-29T16:50:30","modified_gmt":"2026-03-29T15:50:30","slug":"harm-hardship-and-the-price-of-inaction-examining-the-costs-of-scotlands-drug-crisis","status":"publish","type":"post","link":"https:\/\/drugprevent.org.uk\/ppp\/2026\/03\/harm-hardship-and-the-price-of-inaction-examining-the-costs-of-scotlands-drug-crisis\/","title":{"rendered":"Harm, hardship, and the price of inaction: Examining the costs of Scotland\u2019s drug crisis"},"content":{"rendered":"<div class=\"single-post-title-block Blue\">\n<div class=\"site-width\">\n<div class=\"single-post-left left two-third\"><\/div>\n<\/div>\n<\/div>\n<div class=\"single-post-content-block Blue\">\n<div class=\"site-width Black\">\n<div class=\"single-post-left left two-third\">\n<div class=\"single-post-meta page-row-pb\">\n<div class=\"single-post-date aos-init aos-animate\" data-aos=\"zoom-in\"><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff;\">\u00a0<\/span><\/div>\n<div class=\"single-post-author aos-init aos-animate\" data-aos=\"zoom-in\"><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff;\">AUTHOR(S):\u00a0Jake Shepherd,\u00a0Jamie Gollings,\u00a0Barney Dowling\u00a0 &#8211; 25 March 2026<\/span><\/div>\n<\/div>\n<div class=\"single-post-intro-text Blue aos-init aos-animate\" data-aos=\"fade-up\">\n<p><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\">Scotland\u2019s drug crisis carries a profound toll, with hundreds of lives lost each year. As well as these human impacts, the crisis imposes considerable financial costs that are likely to shape future decision-making. This report presents new economic analysis of those costs, examining their consequences across the public sector and the wider Scottish economy.<\/span><\/p>\n<p><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\">Drawing on qualitative insights from policy experts, service leaders, and clinicians, as well as people who use drugs, the research explores the measures the new Scottish Government can take to alleviate the crisis. It ultimately advocates for a full-spectrum approach, spanning harm reduction and recovery-focused interventions.<\/span><\/p>\n<\/div>\n<div class=\"aos-init aos-animate\" data-aos=\"fade-up\">\n<h3><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>KEY FINDINGS<\/strong><\/span><\/h3>\n<ul>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>Scotland\u2019s drug death rate is exceptionally high.<\/strong>\u00a0The crisis is closely linked to deprivation and structural inequalities, with deindustrialisation, social displacement, and hardship shaping the conditions in which harmful drug environments can develop. It should not be treated as an individual failing.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>In recent years, the crisis has taken on new dimensions,<\/strong>\u00a0such as the rise of polydrug deaths and the emergence of powerful synthetic opioids.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>People with lived and living experience of drug use in Glasgow and Edinburgh described what is in their view an increasingly pervasive drugs market<\/strong>, alongside concerns that support services are difficult to access.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>New economic modelling estimates that drug harm has a direct cost to the state of up to \u00a31 billion every year in Scotland<\/strong>, including \u00a3220 million in healthcare and drug services costs and \u00a3320 million on crime and justice.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>Total social and economic costs are estimated to be as much as \u00a35.7 billion annually.<\/strong>\u00a0As well as public sector impacts, this includes \u00a31.2 billion in lost output from employment and \u00a33.5 billion in social costs from deaths, lost quality of life, and victim costs.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>There is extensive evidence\u00a0 that relatively low-cost interventions can reduce harm and prevent deaths.\u00a0<\/strong>Needle and syringe programmes and naloxone \u2013 an opioid overdose antidote \u2013 are highly cost-effective and may even be cost-saving. Interventional evidence also supports drug checking services and safer drug consumption facilities.<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>RECOMMENDATIONS<\/strong><\/span><\/h3>\n<ul>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>Policymakers should take a\u00a0primarily\u00a0public health-led approach to drug harm,<\/strong>\u00a0prioritising prevention, harm reduction, treatment, and support \u2013 \u00a0a more effective approach than one based on\u00a0punishment and criminalisation.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>The most immediate priority should be to prevent deaths<\/strong>,\u00a0through sustaining naloxone and needle and syringe exchange programmes, expanding drug checking services, and rolling out safer drugs consumption facilities.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>These approaches should also work alongside treatment and recovery services to provide a full spectrum of support<\/strong>,\u00a0including widening Medication-Assisted Treatment (MAT)-style treatments, increasing detox capacity, and closing gaps in residential rehabilitation.<\/span><\/li>\n<li><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff; font-size: 10pt;\"><strong>In terms of longer-term measures, action should include sustained investment from the Scottish Government to back up its new Alcohol and Drugs Plan,\u00a0<\/strong>including expanding preventative support. The UK Government should carry out a comprehensive review of drugs policy, including the possibility of legislative reform.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-family: verdana, geneva, sans-serif; color: #0000ff;\">Source: https:\/\/www.smf.co.uk\/publications\/scottish-drugs-crisis\/<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 AUTHOR(S):\u00a0Jake Shepherd,\u00a0Jamie Gollings,\u00a0Barney Dowling\u00a0 &#8211; 25 March 2026 Scotland\u2019s drug crisis carries a profound toll, with hundreds of lives lost each year. As well as these human impacts, the crisis imposes considerable financial costs that are likely to shape future decision-making. This report presents new economic analysis of those costs, examining their consequences across [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[68,82,142,128],"tags":[],"class_list":["post-20849","post","type-post","status-publish","format-standard","hentry","category-drug-use-various-effects","category-economic","category-latest-news","category-uk"],"_links":{"self":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20849","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/comments?post=20849"}],"version-history":[{"count":1,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20849\/revisions"}],"predecessor-version":[{"id":20850,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/posts\/20849\/revisions\/20850"}],"wp:attachment":[{"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/media?parent=20849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/categories?post=20849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugprevent.org.uk\/ppp\/wp-json\/wp\/v2\/tags?post=20849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}